| Literature DB >> 34222261 |
Hongfu Jin1,2, Shigang Jiang3, Ruomei Wang4, Yi Zhang1,2, Jiangtao Dong3, Yusheng Li1,2.
Abstract
Osteoarthritis (OA), one of the most common degenerative diseases, is characterized by progressive degeneration of the articular cartilage and subchondral bone, as well as the synovium. Integrins, comprising a family of heterodimeric transmembrane proteins containing α subunit and β subunit, play essential roles in various physiological functions of cells, such as cell attachment, movement, growth, differentiation, and mechanical signal conduction. Previous studies have shown that integrin dysfunction is involved in OA pathogenesis. This review article focuses on the roles of integrins in OA, especially in OA cartilage, subchondral bone and the synovium. A clear understanding of these roles may influence the future development of treatments for OA.Entities:
Keywords: cartilage; integrin; mechanical signal conduction; osteoarthritis; subchondral bone; synovial membrane
Year: 2021 PMID: 34222261 PMCID: PMC8250141 DOI: 10.3389/fcell.2021.693484
Source DB: PubMed Journal: Front Cell Dev Biol ISSN: 2296-634X
FIGURE 1Integrins undergo many changes in OA, suggesting integrins participate in pathological processes of OA. Recent studies have identified the important role of integrins in OA cartilage, as well as subchondral bone and synovium.
FIGURE 2The RGD-containing fibronectin fragments (Fn-fs) can induce cartilage damage and proteoglycan loss. PKCδ is the rate-limiting factor at the convergent point of signaling input from Fn-fs. PKCδ activation can lead to nuclear factor kappaB (NF-κB) activation in addition to MAP kinase (MAPK) activation. MAPKs (ERK1/2, JNK1/2, and p38) activation can lead to inhibition of anabolic signaling, including IGF-1 and BMP7 signaling pathways, increased levels of inflammatory cytokines and upregulation of catabolic proteases like MMP-3 and MMP-13.
Recent experiments on treating OA by interfering with integrin-mediated signaling pathways.
| Integrin-β-like 1 (Itgbl1) | Interact with integrins to down-regulate activity. | In patients with osteoarthritis (OA), the expression of Itgbl1 is greatly reduced. The ectopic expression of Itgbl1 can protect articular cartilage from the development of OA. | |
| locus-1 (Del1) | Integrin αVβ3-ERK/AKT signaling pathway. | DEL1 protected chondrocytes from apoptosis induced by various activators through integrin αVβ3-mediated signal pathways. | |
| Mechanical exposure and diacerein treatment | Integrin-FAK/STAT3-MAPKs signaling pathway. | In OA chondrocytes a significant reduction in the expression of Piezo1 was detected following treatment with diacerein, even in the presence of mechanical stimulation. | |
| Collagen type II (COL2A1) | Promote the interactions between integrin β1 and SMAD1. | COL2A1 can inhibit BMP-SMAD1-mediated chondrocyte hypertrophy. | |
| Cilengitide | Inhibit integrin αVβ3/αVβ5-FAK-MAPK signaling pathway. | Cilengitide can suppress inflammation in chondrocytes under excessive mechanical stress by interfering integrin-mediated signaling pathway | |
| Cationic solid lipid nanoparticles loaded by integrin β1 plasmid DNA | Enforce the expression of integrin β1. | SLNs-pDNA treatment can reduce the apoptosis of rat chondrocytes and enhance tissue repair, which can be used as a potential non-drug in the treatment of OA. | |
| Exogenic TGF-β1 and WISP1 protein | Interact with Integrin α5 or Integrin αv. | TGF-β1 and WISP1 interact to induce CHs dedifferentiation, which was mainly mediated by integrin αV. However, Integrin αV showed a protective effect. | |
| Vitronectin (VTN) fragment | Interact with αVβ6 in human fibroblast-like synoviocytes. | VTN could prevent TGF-β1 activation by interacting with αVβ6 in human FLSs and increase the level of α-SMA. | |
| Angiopoietin-like proteins (ANGPTLs) | Integrin α5β1- ERK/p38/JNK-NF-κB signaling pathway. | ANGPTL2 enhanced the gene expression of inflammatory mediators, while pretreatment with anti-LILRB2 antibody for 12 h reduced the inflammatory response. |